2009 Communication Pharmaceutical Companies 
Drug Patent Watch
JANUARY 14, 2025
Key Stakeholders in Pharmaceutical Negotiations Successful negotiations in the pharmaceutical industry require a deep understanding of the various stakeholders involved. These may include: Pharmaceutical companies (big pharma and biotech firms) Contract research organizations (CROs) Regulatory bodies (e.g.,
PharmaState Academy
DECEMBER 18, 2024
Scientific Communication for Pharma Marketing - Quiz Questions: 20 Passing Marks: 80% The number of attempts remaining is 1 Please fill in the required information to participate in the Quiz Competition. a) 60% b) 80% c) 40% d) 30% 6 / 20 What is the impact of personalized scientific communication on HCPs?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
NOVEMBER 26, 2020
Since the start of the year, pharmaceutical companies have been riding a rollercoaster of challenges. As the industry moves from a face-to-face to digital communication model, it needs a change of mindset, he adds. “A Pawlu describes a “perfect storm” as the various strands came together to threaten supply chains.
Eye on FDA
SEPTEMBER 28, 2022
FDA published notice recently that the Office of Prescription Drug Promotion (OPDP) was proposing some new research related to the promotion of medicines by pharmaceutical companies. That is particularly true given that the 2009 framework has only been partially addressed by the agency. But for now, we wait.
pharmaphorum
JUNE 14, 2021
In this episode of our Health Innovators series, Paul Tunnah interviews Graeme Duncan, CEO of specialty pharmaceutical company Advanz Pharma. Graeme discusses his career in the life sciences industry and how Advanz Pharma positions itself as the go-to partner for companies commercialising complex medicines in Europe.
Eye on FDA
JANUARY 9, 2022
As noted in the past, there are two primary means for understanding the agency’s latest thinking with respect to promotional communications from pharmaceutical companies – the content and pattern of enforcement and the issuance of guidance documents to shed light on the parameters that exist.
European Pharmaceutical Review
JANUARY 25, 2024
7 Access to digital communications also remains a challenge in some Member States especially for those groups at risk of poverty and social exclusion (7.6 The responsibility of printing paper leaflets is currently a key regulatory obligation for pharmaceutical companies. Article 63 EMA (29 January 2020).
Expert insights. Personalized for you.
64 
Let's personalize your content